Dutch deep tech start-up Reyedar, previously know as Reperio Medtech, uses eye-tracking sensors coupled with deep learning to detect early symptoms of age-related degenerative diseases such as glaucoma, parkinson’s, and multiple sclerosis. Early diagnosis is expected to improve the outcome of treatment and also health care costs.
The company is a spin-out of the Ophthalmology Department of the University Medical Center Groningen. It has secured €3 million in funding giving it the opportunity to commercialise its tech.
"With this funding, we will grow our team, launch our first product in the eye care market, expand our product offering, and ultimately improve the lives of millions of people affected by age-related degenerative diseases,” says Dr. Alessandro Grillini, founder and CEO of Reyedar.
The funding round is led by Cottonwood Technology Fund and joined by NOM, Pupil Labs, Uneti Ventures, and existing investor Blue Sparrows MedTech Fund.
"It is very exciting to lead this investment in Reyedar and support the development of this ground-breaking technology," said Patrick Claessen, Partner of Cottonwood Technology Fund. "Reyedar has an experienced team and developed an impressive technology platform that translates eye movement to actionable medical insights. The company has the potential to make a huge positive impact on human lives by healthier ageing for millions of people."
"We are delighted to participate in this funding round for Reyedar," said Annemieke Wouterse, Senior Investment Manager at NOM. "The company's innovative technology offers early detection of multiple degenerative diseases using the eyes as a window into one’s health. This technology significantly reduces waiting lists in the health sector, and we look forward to working with the team to bring their technology to market."
Would you like to write the first comment?
Login to post comments